Posted by Michael Wonder on 24 Feb 2020
Seqirus receives FDA approval for Fluad Quadrivalent (influenza vaccine, adjuvanted) for adults 65 years and older
24 February 2020 - Designed with MF59 adjuvant to help strengthen, broaden and lengthen the body's immune response against the influenza strains contained in the vaccine.
Seqirus announced today that the U.S. FDA has approved the first adjuvanted quadrivalent influenza vaccine, Fluad Quadrivalent (influenza vaccine, adjuvanted), to help protect adults 65 years and older against seasonal influenza.
